Clifford Chance
Clifford Chance advises international pharmaceutical group Recordati on its $845 million acquisition of EUSA Pharma
13 April 2022
- Nelson Jung, Michael Rueter, Deepaloke Chatterjee, Dani Rabinowitz, Sian Fagan, Dimitri Slobodenjuk, Anne Filzmoser, Caroline Scholke, , , , Eva Kurban (She/Her), Isa Herrera Moya, Dani Rabinowitz, Hendrik Coppoolse
- London, Düsseldorf, Paris, Washington D.C.
Clifford Chance advises international pharmaceutical group Recordati on its $845 million acquisition of EUSA Pharma
Clifford Chance has advised Recordati Industria Chimica e Farmaceutica S.p.A. (Recordati), an international pharmaceutical group listed on the Italian Stock Exchange, and a portfolio company of CVC Capital Partners Fund VII, on the multijurisdictional merger and foreign investment filings for its acquisition of EUSA Pharma (UK) Limited (EUSA Pharma) for an enterprise value of $845 million.
EUSA Pharma is a global speciality pharmaceutical company focused on rare and niche oncology diseases.
Partner Nelson Jung led the international team and was supported by senior associate Michael Rueter, associates Deepaloke Chatterjee, Dani Rabinowitz and Sian Fagan in London, partner Dimitri Slobodenjuk, senior associates Anne Filzmoser and Caroline Scholke in Düsseldorf, counsel Emily Xueref-Poviac and associate Hendrik Coppoolse in Paris, partner Timothy Cornell, counsel Tarica Chambliss, associates Eva Kurban and Isa Herrera Moya in Washington, DC.
